Point72 Asset Management
AVXL icon

Point72 Asset Management’s Anavex Life Sciences AVXL Stock Holding History

Point72 Asset Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-222,300
Closed -$2.07M – 2171
2023
Q4 		$2.07M Buy
+222,300
New +$1.53M 0.01% 1194

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Point72 Asset Management's AVXL Position: Q1 2026 in Review

Point72 Asset Management sold out of Anavex Life Sciences (AVXL) in Q1 2026, closing a stake of 278,018 shares — an estimated $990K sold.

Point72 Asset Management first reported a position in AVXL in Q4 2025 and held it in 1 quarter. The position peaked at $990K in Q4 2025. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • Point72 Asset Management reported no remaining Anavex Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 278,018 Anavex Life Sciences shares in Q1 2026, an estimated $990K.
  • Point72 Asset Management first reported a position in Anavex Life Sciences in Q4 2025 and held it in 1 quarter.
  • Point72 Asset Management's Anavex Life Sciences position peaked at $990K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.